NCT04283526View on ClinicalTrials.gov

Study of Select Combinations in Adults With Myelofibrosis

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2020

Primary Completion Date

April 11, 2024

Study Completion Date

April 11, 2024

Conditions
Primary MyelofibrosisMyelofibrosisPMFPost-Essential Thrombocythemia MyelofibrosisPost-Polycythemia Vera Myelofibrosis
Interventions
DRUG

MBG453

Intravenous. 600mg. Every first day of a 21-day cycle, or on days 8 and 29 of a 42-day cycle (when in combination with Decitabine).

DRUG

NIS793

Intravenous. 2100mg. Every first day of a 21-day cycle, or on days 8 and 29 of a 42-day cycle (when in combination with Decitabine).

DRUG

Spartalizumab

Intravenous. 300mg. Every first day of a 21-day cycle

DRUG

Decitabine

Intravenous. Starting dose: 5mg/m2 (dose cap at 20mg/m2). On days 1, 2 and 3 of a 42-day cycle

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY